APL-9796, a novel anti-ZIP12 antibody, reduces zinc-mediated hyperproliferation and vasoconstriction in pulmonary arterial hypertension cell models.
Background
Pulmonary arterial hypertension (PAH) is a severe vascular disorder marked by excessive pulmonary vasoconstriction and arterial remodeling, leading to progressive right heart failure. Current therapies often fall short in fully reversing disease progression. Disrupted intracellular zinc homeostasis has emerged as a key contributor to PAH pathogenesis, with the zinc transporter ZIP12 identified as upregulated in idiopathic PAH (IPAH) patients. ZIP12 mediates zinc influx, and its dysregulation drives pathological cellular behaviors like proliferation and metabolic reprogramming, representing a critical, underexplored therapeutic target.
Study Design
Researchers investigated the effects of APL-9796, a novel humanized monoclonal antibody designed to inhibit ZIP12, on cellular dysfunction in PAH. They used pulmonary artery fibroblasts (PAAFs) derived from IPAH patients and pulmonary smooth muscle cells (PASMCs) stimulated with hypoxia or platelet-derived growth factor (PDGF). Western blot analysis confirmed ZIP12 upregulation in these cell models. High-throughput FRET-based zinc imaging measured intracellular labile zinc, while BrdU incorporation assays assessed cell proliferation. Stress fiber formation and myosin light chain phosphorylation were also evaluated to gauge vasoconstrictive responses.
Results
ZIP12 upregulation was confirmed in IPAH-derived PAAFs and in PASMCs exposed to hypoxia or PDGF. These cells exhibited elevated intracellular labile zinc, a key pathological finding. > APL-9796 treatment significantly attenuated the elevated intracellular labile zinc levels in both IPAH PAAFs and stimulated PASMCs. Furthermore, APL-9796 effectively reduced hyperproliferation in IPAH PAAFs and in PDGF/hypoxia-stimulated PASMCs, as measured by BrdU incorporation. The antibody also reduced stress fiber formation and myosin light chain phosphorylation, indicating a suppression of the cellular mechanisms underlying vasoconstriction. These findings collectively demonstrate that targeting ZIP12 with APL-9796 can modulate critical pathological processes in PAH.
Key Findings
- Zinc transporter
ZIP12is upregulated in IPAH patient-derived cells and stimulatedPASMCs. - IPAH cells and stimulated
PASMCsexhibit elevated intracellular labile zinc. - APL-9796 significantly attenuated elevated intracellular labile zinc levels.
- APL-9796 reduced hyperproliferation in IPAH PAAFs and stimulated
PASMCs. - APL-9796 reduced stress fiber formation and myosin light chain phosphorylation, indicating suppressed vasoconstriction.
Why It Matters
This study highlights a novel therapeutic strategy for pulmonary arterial hypertension by targeting ZIP12 and intracellular zinc. For biohackers and clinicians, APL-9796 represents a potential new class of intervention that directly addresses a fundamental cellular dysregulation in PAH, moving beyond current vasodilatory approaches. The ability to modulate zinc homeostasis and reduce hyperproliferation and vasoconstriction could offer a disease-modifying effect. While currently in preclinical cell models, these findings suggest that a humanized monoclonal antibody like APL-9796 could eventually translate into a clinical treatment, potentially improving outcomes for patients with IPAH. Further research is needed to develop a usable protocol and assess in vivo efficacy and safety.